Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07619482 · ClinicalTrials.gov registry record · Phase 1
Topical Insulin for Glaucoma (TING2)
A Phase 1 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07619482: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT07619482 is a Phase 1 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 90 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07619482, a Phase 1 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1/2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.
Primary Outcome
Safety of topical sterile human insulin (EYED-002) in patients with open-angle glaucoma. AEs and SAEs classified using MedDRA nomenclature, assessed for severity (mild, moderate, severe) and causality. Safety monitoring includes glycemia measurements before and 2 hours after in-clinic insulin administration, and serial serum electrolyte (potassium) measurements.
Interventions
- DRUG EYED-002 Low Dose (721 U/mL topical insulin)
- DRUG EYED-002 High Dose (1442 U/mL topical insulin)
- DRUG EYED-002 (highest tolerated dose, 12-month)
- DRUG Vehicle Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-10 |
| Phase | Phase 1 |
What is known before NCT07619482 opens enrollment
NCT07619482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 4 interventions - of which EYED-002 Low Dose (721 U/mL topical insulin) is the first listed.
NCT07619482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07619482 about?
NCT07619482 is a clinical study titled "Topical Insulin for Glaucoma (TING2)". This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1/2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-fre...
What is the current status of trial NCT07619482?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-06. Estimated completion is 2029-10.
What interventions are being tested in trial NCT07619482?
The interventions under investigation include: EYED-002 Low Dose (721 U/mL topical insulin) (DRUG), EYED-002 High Dose (1442 U/mL topical insulin) (DRUG), EYED-002 (highest tolerated dose, 12-month) (DRUG), Vehicle Placebo (DRUG).
Who is sponsoring clinical trial NCT07619482?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07619482's enrollment target sits among peer trials
90 628th of 2000 higher than 1,352 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia